August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, Sapient passed a rigorous evaluation process that involved an in-depth inspection of its clinical laboratory facilities, equipment, processes, quality control measures, and personnel qualifications.
“As a CLIA-certified lab performing advanced biomarker assays that are deemed ‘high complexity’, we must adhere to the most stringent CLIA regulations. Accreditation by CAP confirms that we uphold or exceed these high standards with exceptional testing proficiency, accuracy, and reliability,” said Nilesh Dharajiya, MD, CLIA Lab Director at Sapient. “I’m incredibly proud of our team to be recognized by CAP for their diligence and commitment to excellence in every aspect of our clinical lab operations.”

“The results from the biomarker tests we develop and perform under CLIA can be used to direct patient care, be it for diagnosing disease, to identify responders vs. non-responders to a specific drug, or to evaluate drug safety and dosing strategies during clinical trials,” said Mo Jain, MD, PhD, Founder and CEO of Sapient. “Our clients rely on this data to guide their decision-making and ensure patient safety. It was very important for us to pursue CAP accreditation, to give customers the utmost confidence in our ability to develop robust clinical tests and provide accurate results that adhere to strict regulatory requirements.”
“As an organization, we are committed to upholding a culture of quality and to thoughtfully evolving our service offerings to meet the needs of our clients,” Dr. Jain continued. “With our CLIA-certified, CAP-accredited laboratory, we are able to support rapid translation of the biomarker discoveries we make for our biopharma customers to regulated clinical applications, and to further accelerate development and deployment of much-needed diagnostics and therapies.”
###
About Sapient
Sapient is a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, using state-of-the-art, high-throughput mass spectrometry technologies that enable rapid, non-targeted measure of thousands of small molecule biomarkers in human, preclinical, and cellular biosamples. These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale spectral data, robust quality control analysis, and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using its proprietary in-house longitudinal Human Biology Database that includes mass spectrometry measures from over 100,000 human biosamples linked with corresponding clinical and multi-dimensional -omics data. Together these approaches enable rapid identification, validation, and translation of small molecule biomarkers of biological processes, disease mechanisms, and drug responsiveness across all drug development phases. For more information, visit sapient.bio.
Media Contact:
Carla Nieser
Head of Marketing, Sapient
carla.nieser@sapient.bio
858.290.7010

Sapient’s High Complexity CLIA Laboratory Receives Accreditation from the College of American Pathologists (CAP)
August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, Sapient passed a rigorous evaluation… Read More

Biocom LifeLines Magazine Feature: “Illuminating unknowns in the dynamic interplay of genetics, environment, and disease”
Biocom California recently asked Sapient to contribute an article for its Lifelines Magazine, a forum sharing insights and innovations that are leading the way for life science. We discuss why discovery of dynamic, non-genetic biomarkers is needed to elucidate still-unknown contributors and causes of disease, and… Read More

Technology Networks Feature: “Probing the Biomarker Landscape of Human Disease”
Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker discovery and how next-generation mass spectrometry (MS)-based systems can help to fill the current gap in biomarker technologies. Read an excerpt from the… Read More

Sapient Featured in Biocompare Article, “Mass Spectrometry for Biomarker Discovery”
Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes on the challenges and opportunities of using mass spectrometry for biomarker discovery and research. Dr. Jain shares his perspectives on how technological advances in mass spectrometry are “releasing the brakes”… Read More

University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes & Endocrinology, detailing findings which identify putative metabolic pathways that influence fetal growth trajectories and childhood health outcomes. Sapient provided mass spectrometry-based discovery metabolomics… Read More

Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases. Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating… Read More

Sapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry Analysis
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention, and disease-treatment interventions July 11, 2022—San Diego, CA—Sapient, a biomarker discovery organization focused on rapid, large-scale biomarker profiling, has been awarded a… Read More

Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one… Read More

Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to… Read More

Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report
San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area Lyme Foundation’s 2021 Impact Update report for its collaboration with the Foundation aimed at establishing new diagnostics for persistent Lyme disease (PLD). The report… Read More